



# Tajikistan: COVID-19 Vaccine Support Project under the Asia Pacific Vaccine Access Facility

Project Name	COVID-19 Vaccine Support Project under the Asia Pacific Vaccine Access Facility	
Project Number	55078-001	
Country	Tajikistan	
Project Status	Active	
Project Type / Modality of Assistance	Grant	
Source of Funding / Amount	Grant 0791-TAJ: COVID-19 Vaccine Support Project under the Asia Pacific Vaccine Access Facility	
	Asian Development Fund	US\$ 25.00 million
Strategic Agendas	Inclusive economic growth Regional integration	
Drivers of Change	Partnerships	
Sector / Subsector	Health - Disease control of communicable disease	
Gender Equity and Mainstreaming	Effective gender mainstreaming	
Description	The project responds to the government's request for ADB support under APVAX to help meet COVID-19 vaccine response challenges. In accordance with the guidance of the APVAX policy, the project investment component under APVAX will support ADB's procurement and project implementation, which will benefit Tajikistan given due diligence assessments that identified fiduciary-related risks.	
Project Rationale and Linkage to Country/Regional Strategy	COVID-19 rapidly accelerated into a global pandemic, as declared by the World Health Organization (WHO) on 11 March 2020. The number of cases grew exponentially across countries and continents, resulting in closed borders; travel restrictions; lockdowns; national health crises; and disruptions in trade, investment, tourism, and remittance flows. Tajikistan confirmed its first 15 cases of COVID-19 on 30 April 2020 and, by 28 February 2021, that number had risen to 13,308. Tajikistan also confirmed 90 deaths. Only 407,841 tests were completed in Tajikistan up to 28 February 2021, indicating a high probability of undetected cases. The country is ill-equipped to handle large-scale health crises and remains highly vulnerable to the COVID-19 pandemic. Limited testing capacity and absence of strict social distancing and self-isolation measures have led to increasing pressures in the health system.	
Impact	Vulnerable groups protected from morbidity and mortality caused by COVID-19 The spread of the SARS-CoV-2 virus reduced and confidence of citizens restored	
<b>Project Outcome</b>		
Description of Outcome	Priority populations vaccinated against COVID-19	
Progress Toward Outcome		
<b>Implementation Progress</b>		
Description of Project Outputs	COVID-19 vaccines procured and delivered to designated delivery points Vaccine program implementation capacity strengthened	
Status of Implementation Progress (Outputs, Activities, and Issues)		
Geographical Location	Nation-wide	
<b>Safeguard Categories</b>		
Environment	C	
Involuntary Resettlement	C	
Indigenous Peoples	C	
<b>Summary of Environmental and Social Aspects</b>		
Environmental Aspects		
Involuntary Resettlement		
Indigenous Peoples		
<b>Stakeholder Communication, Participation, and Consultation</b>		
During Project Design		
During Project Implementation		
Responsible ADB Officer	Concepcion, Rhodora B.	
Responsible ADB Department	Central and West Asia Department	
Responsible ADB Division	Tajikistan Resident Mission	

Timetable	
Concept Clearance	-
Fact Finding	11 Mar 2021 to 12 Apr 2021
MRM	30 Mar 2021
Approval	16 Jun 2021
Last Review Mission	-
Last PDS Update	16 Jun 2021

## Grant 0791-TAJ

Milestones					
Approval	Signing Date	Effectivity Date	Closing		
			Original	Revised	Actual
16 Jun 2021	21 Jun 2021	12 Jul 2021	31 Dec 2023	-	-

Financing Plan		Grant Utilization			
	Total (Amount in US\$ million)	Date	ADB	Others	Net Percentage
Project Cost	26.80	Cumulative Contract Awards			
ADB	25.00	18 Oct 2021	23.98	0.00	96%
Counterpart	1.80	Cumulative Disbursements			
Cofinancing	0.00	18 Oct 2021	23.40	0.00	94%

Project Page	<a href="https://www.adb.org/projects/55078-001/main">https://www.adb.org/projects/55078-001/main</a>
Request for Information	<a href="http://www.adb.org/forms/request-information-form?subject=55078-001">http://www.adb.org/forms/request-information-form?subject=55078-001</a>
Date Generated	03 November 2021

ADB provides the information contained in this project data sheet (PDS) solely as a resource for its users without any form of assurance. Whilst ADB tries to provide high quality content, the information are provided "as is" without warranty of any kind, either express or implied, including without limitation warranties of merchantability, fitness for a particular purpose, and non-infringement. ADB specifically does not make any warranties or representations as to the accuracy or completeness of any such information.